Dr. Vokes Discusses Patient Characteristics and Immunotherapy in NSCLC

Everett Vokes, MD
Published: Tuesday, Jul 31, 2018



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses patient characteristics when considering immunotherapy in stage III non-small cell lung cancer (NSCLC).

Up until this past year, the typical standard approach to treating patients with stage III NSCLC was a combination of chemotherapy and radiotherapy. In February 2018, the FDA has approved durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III NSCLC who have not progressed following chemoradiotherapy.

Characteristics that might deter a physician from choosing immunotherapy in a patient with stage III NSCLC is autoimmune disease, Vokes says. Other subsets of patients such as those with poor performance status might also need to be evaluated before treatment with an immunotherapy agent such as durvalumab. Although, Vokes says that if a less fit patient is successful after chemoradiotherapy, then additional treatment should be considered.


Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses patient characteristics when considering immunotherapy in stage III non-small cell lung cancer (NSCLC).

Up until this past year, the typical standard approach to treating patients with stage III NSCLC was a combination of chemotherapy and radiotherapy. In February 2018, the FDA has approved durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III NSCLC who have not progressed following chemoradiotherapy.

Characteristics that might deter a physician from choosing immunotherapy in a patient with stage III NSCLC is autoimmune disease, Vokes says. Other subsets of patients such as those with poor performance status might also need to be evaluated before treatment with an immunotherapy agent such as durvalumab. Although, Vokes says that if a less fit patient is successful after chemoradiotherapy, then additional treatment should be considered.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x